FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082568045> ?p ?o ?g. }

• W2082568045 abstract "Background: Hsp90 is a molecular chaperone protein required for the stabilization and activation of many proteins, referred to as Hsp90 ‘clients’, such as HER2, HIF1-a, EGFR, ER, PI3K, AKT, P53 and VEGFR. The drug candidate, ganetespib is a novel triazolone inhibitor of Hsp90, with over 700 patients treated to date. Ganetespib has shown activity in preclinical models of HER2+, ER+/PR+ and TNBC. Early clinical trials documented ganetespib single agent activity in heavily pretreated HER2+ and TNBC patients. Ganetespib has been well tolerated in clinical trials with a favorable safety profile. This efficacy-screening study is designed to provide further evidence of ganetespib activity and identify potentially predictive biomarkers in metastatic breast cancer (BC). Methods: The ENCHANT-1 Trial is an international, first-line 2-cohort Phase 2 study in BC patients: Cohort A, HER2 amplified (n = 35), and Cohort B, TNBC (n = 35). Patients who present with previously untreated metastatic disease are eligible for treatment with ganetespib at 150 mg/m2 twice weekly on 3 out of 4 wks, for a total of up to 12 wks. Primary endpoint: ORR assessed using RECIST1.1 criteria. Key secondary endpoints include metabolic response as assessed by PET/CT at wk 3 utilizing modified EORTC criteria. Disease progression (PD) at wk 3 by PET imaging indicates discontinuation of study therapy, and is performed to quickly offer patients with metabolic PD a standard of care treatment. The study is designed as Simon 2-stage requiring at least one OR in 15 patients for the respective cohort to expand to 35 patients. A Steering Committee is established to oversee the overall study and review the interim results. Results: The study was initiated in 23 centers globally. At the time of submission, a total of 17 patients had been enrolled; TNBC (n = 15) and HER2 (n = 2). Here we report the interim analysis in the TNBC cohort. The median age was 54 years (range 30 -77) with ECOG PS 0 (n = 7/15). Most patients (n = 9) presented with de novo metastatic disease. 5 patients were not evaluable for PET assessment (3 had not yet reached wk 3 and 2 withdrawn before wk 3 for clinical progression), and 9 patients were not evaluable for objective response at wk 6 (3 withdrawn before or at wk 3 for clinical progression and 6 had not yet reached wk 6 evaluation). In the 10 patients with evaluable PET imaging, 9 patients achieved metabolic (m) response (2 mPR, 4 mSD with dominant tumor shrinkage and 3 SD) and one patient with mPD. In the 6 patients evaluable for OR at wk 6, one patient achieved PR, 2 SD and 3 PD. Treatment with ganetespib was well tolerated; the most common AEs were mild or moderate diarrhea (8/15, 53%), fatigue (5/15, 33%), decreased appetite (4/15, 27%), insomnia (4/15, 27%), and nausea (4/15, 27%). Conclusion: Ganetespib single agent was generally well tolerated and showed anti-tumor activity TNBC patients as early as 3 weeks following treatment. PET seems to be a good tool to screen antitumor activity of new agents in early settings rather that in heavily pretreated patients. The TNBC cohort has met the protocol criteria for proceeding to stage 2. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-23." @default.
• W2082568045 created "2016-06-24" @default.
• W2082568045 creator A5003272024 @default.
• W2082568045 creator A5006092493 @default.
• W2082568045 creator A5006629343 @default.
• W2082568045 creator A5008165251 @default.
• W2082568045 creator A5008767871 @default.
• W2082568045 creator A5012602285 @default.
• W2082568045 creator A5026426994 @default.
• W2082568045 creator A5026610840 @default.
• W2082568045 creator A5028001208 @default.
• W2082568045 creator A5031675404 @default.
• W2082568045 creator A5032661607 @default.
• W2082568045 creator A5036907815 @default.
• W2082568045 creator A5040456720 @default.
• W2082568045 creator A5045326366 @default.
• W2082568045 creator A5056927697 @default.
• W2082568045 creator A5063064622 @default.
• W2082568045 creator A5078523501 @default.
• W2082568045 creator A5081661047 @default.
• W2082568045 creator A5083324152 @default.
• W2082568045 creator A5083955910 @default.
• W2082568045 creator A5086474233 @default.
• W2082568045 creator A5089701845 @default.
• W2082568045 creator A5091142596 @default.
• W2082568045 date "2013-12-15" @default.
• W2082568045 modified "2023-09-27" @default.
• W2082568045 title "Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)" @default.
• W2082568045 doi "https://doi.org/10.1158/0008-5472.sabcs13-p2-16-23" @default.
• W2082568045 hasPublicationYear "2013" @default.
• W2082568045 type Work @default.
• W2082568045 sameAs 2082568045 @default.
• W2082568045 citedByCount "3" @default.
• W2082568045 countsByYear W20825680452014 @default.
• W2082568045 countsByYear W20825680452015 @default.
• W2082568045 countsByYear W20825680452019 @default.
• W2082568045 crossrefType "proceedings-article" @default.
• W2082568045 hasAuthorship W2082568045A5003272024 @default.
• W2082568045 hasAuthorship W2082568045A5006092493 @default.
• W2082568045 hasAuthorship W2082568045A5006629343 @default.
• W2082568045 hasAuthorship W2082568045A5008165251 @default.
• W2082568045 hasAuthorship W2082568045A5008767871 @default.
• W2082568045 hasAuthorship W2082568045A5012602285 @default.
• W2082568045 hasAuthorship W2082568045A5026426994 @default.
• W2082568045 hasAuthorship W2082568045A5026610840 @default.
• W2082568045 hasAuthorship W2082568045A5028001208 @default.
• W2082568045 hasAuthorship W2082568045A5031675404 @default.
• W2082568045 hasAuthorship W2082568045A5032661607 @default.
• W2082568045 hasAuthorship W2082568045A5036907815 @default.
• W2082568045 hasAuthorship W2082568045A5040456720 @default.
• W2082568045 hasAuthorship W2082568045A5045326366 @default.
• W2082568045 hasAuthorship W2082568045A5056927697 @default.
• W2082568045 hasAuthorship W2082568045A5063064622 @default.
• W2082568045 hasAuthorship W2082568045A5078523501 @default.
• W2082568045 hasAuthorship W2082568045A5081661047 @default.
• W2082568045 hasAuthorship W2082568045A5083324152 @default.
• W2082568045 hasAuthorship W2082568045A5083955910 @default.
• W2082568045 hasAuthorship W2082568045A5086474233 @default.
• W2082568045 hasAuthorship W2082568045A5089701845 @default.
• W2082568045 hasAuthorship W2082568045A5091142596 @default.
• W2082568045 hasConcept C121608353 @default.
• W2082568045 hasConcept C126322002 @default.
• W2082568045 hasConcept C143998085 @default.
• W2082568045 hasConcept C203092338 @default.
• W2082568045 hasConcept C2775930923 @default.
• W2082568045 hasConcept C2778715236 @default.
• W2082568045 hasConcept C31760486 @default.
• W2082568045 hasConcept C530470458 @default.
• W2082568045 hasConcept C535046627 @default.
• W2082568045 hasConcept C71924100 @default.
• W2082568045 hasConcept C72563966 @default.
• W2082568045 hasConceptScore W2082568045C121608353 @default.
• W2082568045 hasConceptScore W2082568045C126322002 @default.
• W2082568045 hasConceptScore W2082568045C143998085 @default.
• W2082568045 hasConceptScore W2082568045C203092338 @default.
• W2082568045 hasConceptScore W2082568045C2775930923 @default.
• W2082568045 hasConceptScore W2082568045C2778715236 @default.
• W2082568045 hasConceptScore W2082568045C31760486 @default.
• W2082568045 hasConceptScore W2082568045C530470458 @default.
• W2082568045 hasConceptScore W2082568045C535046627 @default.
• W2082568045 hasConceptScore W2082568045C71924100 @default.
• W2082568045 hasConceptScore W2082568045C72563966 @default.
• W2082568045 hasLocation W20825680451 @default.
• W2082568045 hasOpenAccess W2082568045 @default.
• W2082568045 hasPrimaryLocation W20825680451 @default.
• W2082568045 hasRelatedWork W2005100930 @default.
• W2082568045 hasRelatedWork W2147847797 @default.
• W2082568045 isParatext "false" @default.
• W2082568045 isRetracted "false" @default.
• W2082568045 magId "2082568045" @default.
• W2082568045 workType "article" @default.